Clinical Trial Update: A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, reactogenicity, and immune responses to an inactivated influenza vaccine targeting H5N1 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza
• Influenza Infection

Drugs mentioned

• Inactivated H5N1 influenza vaccine (inactivated H5N1 influenza vaccine)

Snippet

Sponsor: Medigen Biotechnology Corporation | Conditions: Bird Flu, Avian Influenza | Phase 1 | Status: COMPLETED